[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Murthy R, Honavar SG, Burman S, Vemuganti GK, Naik MN, Reddy VA: Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis. Ophthal Plast Reconstr Surg; 2005 Jul;21(4):307-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in the management of sebaceous gland carcinoma of the eyelid with regional lymph node metastasis.
  • A 55-year-old Asian Indian woman who had recurrent sebaceous gland carcinoma of the left lower eyelid with orbital extension and regional lymph node metastasis was treated with neoadjuvant chemotherapy, using a combination of carboplatin and 5-fluorouracil.
  • Eyelid-sparing orbital exenteration was performed after 3 cycles of chemotherapy, followed by radiotherapy to the regional lymph nodes.
  • Subsequently, 3 cycles of adjuvant chemotherapy were administered.
  • Significant eyelid and orbital tumor volume reduction was achieved with neoadjuvant chemotherapy, making eyelid-sparing orbital exenteration possible.
  • Chemotherapy also spared the patient from radical neck dissection.
  • The patient had limited morbidity and was free of local, regional, and systemic disease at 26 months of follow-up.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052148.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Russell HC, Chadha V, Lockington D, Kemp EG: Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol; 2010 Oct;94(10):1316-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
  • INTRODUCTION: The use of topical mitomycin C (MMC) has gained popularity in the management of ocular surface neoplasia.
  • The aim of this study is to determine outcomes and complications following such treatment.
  • METHODS: This study is a retrospective review of patients treated with topical MMC for ocular surface neoplasia, including primary acquired melanosis (PAM), melanoma, corneal-conjunctival intraepithelial neoplasia (CCIN), squamous cell carcinoma (SCC) and sebaceous gland carcinoma (SGC).
  • Data regarding diagnosis, short- and long-term outcomes, and short- and long-term complications, were recorded.
  • 21 received MMC as primary therapy and 37 as surgical adjuvant.
  • The regimen was 0.04% MMC four times a day for 3 weeks on, 3 weeks off, 3 weeks on, with topical steroid and lubricants throughout.
  • Overall, 26% developed recurrent disease at a mean of 13 months post treatment.
  • Short-term complications occurred in 52%, but only 7% required treatment cessation.
  • CONCLUSION: The results confirm the effectiveness of topical MMC chemotherapy in the management of ocular surface neoplasia.
  • Self-limiting short-term complications were common; however, limbal stem cell deficiency appears to be a significant long-term complication of treatment, occurring in 12%.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


3. Priyadarshini O, Biswas G, Biswas S, Padhi R, Rath S: Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy. Ophthal Plast Reconstr Surg; 2010 Sep-Oct;26(5):366-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy in recurrent sebaceous carcinoma of eyelid with orbital invasion and regional lymphadenopathy.
  • Histopathology showed it to be invasive sebaceous cell carcinoma.
  • At thirty-six weeks after treatment the left eye recorded a visual acuity of finger counting at 1 meter distance and no recurrence.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eyelid Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Orbital Neoplasms / drug therapy. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20856079.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL: Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol; 2005 Mar-Apr;50(2):103-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sebaceous carcinoma of the ocular region: a review.
  • Sebaceous carcinoma of the ocular region is a malignant neoplasm that is being recognized more frequently and managed by innovative techniques of local resection, cryotherapy, topical chemotherapy, and radiotherapy, resulting in improved visual and systemic prognosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Eyelid Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cryotherapy. Eye Neoplasms / pathology. Eye Neoplasms / therapy. Humans. Mohs Surgery. Radiotherapy

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749305.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 168
  •  go-up   go-down


5. Shields CL, Naseripour M, Shields JA, Eagle RC Jr: Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma. Ophthalmology; 2002 Nov;109(11):2129-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin-C for pagetoid invasion of the conjunctiva by eyelid sebaceous gland carcinoma.
  • PURPOSE: To evaluate the efficacy of topical mitomycin-C for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • INTERVENTION: All patients received topical 0.04% mitomycin-C four times daily for 1 week followed by 1 week off medication.
  • The treatment cycles were repeated until resolution of the conjunctival malignancy was clinically evident.
  • PARTICIPANTS: Four patients with histopathologically proven intraepithelial (pagetoid) invasion of the conjunctiva by sebaceous gland carcinoma were managed with this regimen.
  • Before treatment, the main tumor site included the upper eyelid in two cases and the lower eyelid in two cases.
  • Previous resection of the tumor had been performed elsewhere in three cases over the prior 6 years.
  • At the time of our examination, map biopsies confirmed pagetoid invasion involving 25% to 90% of the conjunctival surface, with bulbar, forniceal, and tarsal conjunctival involvement in all four cases and corneal extension in one case.
  • There was no evidence of deep tumor within the conjunctival stroma or tarsus in any case.
  • After treatment, medication intolerance and early discontinuation occurred in one patient, and continued tumor progression was documented.
  • Of the remaining three patients, chemotherapy was used for a mean of four cycles with complete resolution of the pagetoid invasion, confirmed histopathologically in two cases, and without recurrence in all three cases over 12 months (mean) follow-up.
  • The medication caused moderate temporary local irritation but no serious intraocular or extraocular complications.
  • CONCLUSIONS: Preliminary evidence suggests that topical mitomycin-C is effective treatment for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma.
  • Longer follow-up is necessary to assess the duration of tumor control.
  • [MeSH-major] Adenocarcinoma, Sebaceous / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Conjunctival Neoplasms / drug therapy. Eyelid Neoplasms / drug therapy. Mitomycin / therapeutic use. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Neoplasm Invasiveness. Prospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12414427.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


6. Duman DG, Ceyhan BB, Celikel T, Ahiskali R, Duman D: Extraorbital sebaceous carcinoma with rapidly developing visceral metastases. Dermatol Surg; 2003 Sep;29(9):987-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
  • BACKGROUND: Extraorbital sebaceous carcinoma (SC) is a rare carcinoma of the skin but is known to have a good prognosis in terms of metastasis and survival.
  • RESULTS: Local excision of the primary cutaneous tumor with negative margins did not prevent the rapid and fatal internal organ metastases.
  • The patient did not benefit from the docetaxel chemotherapy regimen applied after the distant metastases were developed.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Glandular and Epithelial / pathology. Paclitaxel / analogs & derivatives. Sebaceous Gland Neoplasms / pathology. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Fatal Outcome. Female. Humans. Neoplasm Metastasis. Orbit. Viscera

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12930349.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Shields JA, Demirci H, Marr BP, Eagle RC Jr, Stefanyszyn M, Shields CL: Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture. Ophthal Plast Reconstr Surg; 2005 Mar;21(2):92-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival epithelial involvement by eyelid sebaceous carcinoma. The 2003 J. Howard Stokes lecture.
  • PURPOSE: To determine incidence and distribution of conjunctival epithelial involvement by eyelid sebaceous carcinoma and to make recommendations regarding its management.
  • METHODS: The medical records were reviewed retrospectively on patients with histopathologically confirmed sebaceous carcinoma of the eyelids managed at the Oncology Service at Wills Eye Hospital.
  • The incidence of metastasis and tumor-related mortality was determined.
  • Based on these findings and personal surgical experience, recommendations are made regarding management of eyelid sebaceous carcinoma with involvement of the conjunctival epithelium.
  • RESULTS: Of 60 patients with sebaceous carcinoma, epithelial involvement of the conjunctiva was identified in 28 (47%).
  • Of the 28 cases, the neoplasm affected the following sites: superior tarsal and fornical conjunctiva in 28 (100%), inferior tarsal conjunctiva in 19 (68%), inferior fornical conjunctiva in 18 (64%), superior bulbar conjunctiva in 19 (68%), and inferior bulbar conjunctiva in 16 (57%).
  • Map biopsies, combined with cryotherapy, topical chemotherapy, local surgical resection, and orbital exenteration, were used to achieve local control.
  • CONCLUSIONS: Eyelid sebaceous carcinoma was found to exhibit epithelial involvement of the conjunctiva in 47% of cases, predominantly in the superior tarsal and fornical conjunctiva and less often in the inferior tarsal conjunctiva, caruncle, and cornea.
  • Treatment of this condition is challenging, and map biopsy, cryotherapy, topical chemotherapy, and newer surgical methods are being used more often by our group.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma in Situ / pathology. Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cryotherapy. Humans. Incidence. Ophthalmologic Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778660.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Lectures; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Holbach LM, Pogorelov P, Kruse FE: [Differential diagnosis and treatment options for conjunctival tumors]. Ophthalmologe; 2007 Jun;104(6):521-38; quiz 538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment options for conjunctival tumors].
  • [Transliterated title] Differenzialdiagnose und Therapieoptionen bei Tumoren der Konjunktiva.
  • Essential in practice is the histopathological confirmation of the clinical diagnosis, e.g., distinguishing between nonpigmented melanomas and sebaceous gland carcinomas with a pagetoid growth pattern or squamous cell carcinomas.
  • Depending on the course and findings, the following therapeutic measures can be indicated: cryotherapy, chemotherapy, radiotherapy, modified enucleation, orbital exenteration, or a combination of different methods.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Conjunctiva / pathology. Diagnosis, Differential. Humans. Lymphatic Metastasis / pathology. Melanoma / diagnosis. Melanoma / pathology. Melanoma / therapy. Neoplasm Staging. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Nevus, Pigmented / therapy. Ophthalmoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologe. 2002 Jun;99(6):490-507; quiz 508-9 [12125420.001]
  • [Cites] Orbit. 2000 Mar;19(1):13-19 [12045960.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):674-8 [15224213.001]
  • [Cites] Klin Monbl Augenheilkd. 1999 Oct;215(4):263-5 [10572892.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):163-7 [11815341.001]
  • [Cites] Klin Monbl Augenheilkd. 1995 Oct;207(4):239-46 [8587298.001]
  • [Cites] Klin Monbl Augenheilkd. 1987 Feb;190(2):105-8 [3553717.001]
  • [Cites] Klin Monbl Augenheilkd. 2001 Apr;218(4):269-72 [11392273.001]
  • [Cites] Klin Monbl Augenheilkd. 2002 Jun;219(6):462-4 [12136445.001]
  • [Cites] Curr Opin Ophthalmol. 1995 Aug;6(4):39-43 [10150881.001]
  • [Cites] Br J Ophthalmol. 2001 Jun;85(6):658-61 [11371482.001]
  • [Cites] Klin Monbl Augenheilkd. 1994 Oct;205(4):242-3 [7823524.001]
  • [Cites] Arch Ophthalmol. 2000 Oct;118(10):1437-40 [11030832.001]
  • [Cites] Hum Mutat. 2006 Feb;27(2):155-62 [16395674.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Klin Monbl Augenheilkd. 1986 Aug;189(2):128-32 [3531699.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Ophthalmologe. 2002 May;99(5):394-411; quiz 412-3 [12043298.001]
  • [Cites] Ophthalmologe. 2003 Sep;100(9):708-12 [14504895.001]
  • [Cites] Surv Ophthalmol. 1998 Jan-Feb;42(4):321-50 [9493274.001]
  • [Cites] Am J Ophthalmol. 2002 Jul;134(1):147-8 [12095833.001]
  • [Cites] Eur J Ophthalmol. 1992 Jan-Mar;2(1):3-9 [1322210.001]
  • [Cites] Ophthalmologe. 2006 Feb;103(2):124-8 [16047150.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Klin Monbl Augenheilkd. 1985 Sep;187(3):212-4 [2415746.001]
  • [Cites] Arch Ophthalmol. 2003 Dec;121(12):1776-9 [14662600.001]
  • [Cites] J Fr Ophtalmol. 1995;18(6-7):481-3 [7560791.001]
  • [Cites] Br J Ophthalmol. 1997 Feb;81(2):168 [9059254.001]
  • (PMID = 17530261.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement